Should we move to a genomic classification of neutrophilic myeloid neoplasms?
Blood Adv
.
2023 Nov 14;7(21):6705-6706.
doi: 10.1182/bloodadvances.2023011103.
Authors
Gonzalo Carreño-Tarragona
1
,
Alberto Álvarez-Larrán
2
,
Juan Carlos Hernández-Boluda
3
,
Rosa Ayala
1
,
Nicholas C P Cross
4
5
Affiliations
1
Department of Hematology, Hospital Universitario 12 de Octubre, I+12, CNIO, Complutense University, CIBERONC, Madrid, Spain.
2
Department of Hematology, Hospital Clínic, Barcelona, Spain.
3
Department of Hematology, Hospital Clínico, Valencia, Spain.
4
Wessex Genomic Laboratory Service, Salisbury, United Kingdom.
5
Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
PMID:
37672387
PMCID:
PMC10641471
DOI:
10.1182/bloodadvances.2023011103
No abstract available
Publication types
Comment
MeSH terms
Genomics
Humans
Myeloproliferative Disorders* / genetics
Neoplasms*